Wikipedia:Articles for deletion/Chengdu Kanghong Pharmaceutical Group


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was keep‎__EXPECTED_UNCONNECTED_PAGE__. Liz Read! Talk! 07:22, 19 April 2024 (UTC)

Chengdu Kanghong Pharmaceutical Group

 * – ( View AfD View log | edits since nomination)

The information source in the article is unreliable .Because it does not meet the requirement of Wikipedia:Notability. It is recommended to delete it. Hhhlx (talk) 05:11, 12 April 2024 (UTC)
 * Note: This discussion has been included in the list of Companies-related deletion discussions. Hhhlx (talk) 05:11, 12 April 2024 (UTC)
 * Note: This discussion has been included in the deletion sorting lists for the following topics: Medicine and China.   (talk | contribs) 05:18, 12 April 2024 (UTC)
 * Keep. The first two references are from sources like Xinhua and Reuters, and more can probably be found with a Google News search. There's no need to delete the article. Eastmain (talk • contribs) 06:37, 12 April 2024 (UTC)

Keep per the significant coverage in multiple independent reliable sources.  The summary of the company on the page linking to the report notes: "Chengdu Kanghong Pharmaceuticals Group Co Ltd (Kanghong Pharmaceuticals) focuses on the development, manufacturing and marketing of Chinese medicines, chemical drugs, and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal, and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Yiqing, Keluoxin, Yitanning, and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs, and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China."   The article notes: "康弘药业（002773）的一款核心药品，三年来一直被公司释放“海外临床进展良好”的信号. 然而，随着公司3月29日的一纸“自愿公告”，利好突然变为利空——先是法国临床试验“莫名其妙”被暂停，后是直接宣布临床试验停止. 康弘药业到底是何时获得临床失败信息的？其公告所称“近日”具体指哪一日？康弘药业对这一重大消息的信披是否真实、准确、完整、及时？大量资金为何在消息公布前出逃？" From Google Translate: "A core drug of Kanghong Pharmaceutical (002773), the company has been releasing signals of "good overseas clinical progress" for three years. However, with the company's "voluntary announcement" on March 29, the good news suddenly turned bad - first, the French clinical trial was "inexplicably" suspended, and then the clinical trial was directly announced to be stopped. When did Kanghong Pharmaceutical obtain the clinical failure information? What specific day does the "recent days" mentioned in its announcement refer to? Is Kanghong Pharmaceutical's disclosure of this major news true, accurate, complete and timely? Why did a large amount of money flee before the news was announced?"   The article notes: "公开资料显示，康弘药业是一家致力于中成药、化学药及生物制品的研发、生产、销售的企业，总部位于四川成都. 在资本市场上带有"国内自主研发药企"的耀眼头衔. ... 上世纪九十年代，在华西医科大学附属第一医院药房当主任的柯尊洪离职，与3名同行共同创业. 康弘药业是1998年通过整体收购全民所有制企业济民制药厂后，于2008年3月6日更名而成. "  From Google Translate: "Public information shows that Kanghong Pharmaceutical is an enterprise dedicated to the research and development, production and sales of Chinese patent medicines, chemical drugs and biological products. It is headquartered in Chengdu, Sichuan. ... In the 1990s, Ke Zunhong, who was the director of the pharmacy of the First Affiliated Hospital of West China University of Medical Sciences, resigned and started a business with three colleagues. Kanghong Pharmaceutical was renamed on 6 March 2008 after the overall acquisition of Jimin Pharmaceutical Factory, an enterprise owned by the whole people in 1998."   The article notes: "2018年5月，康弘药业启动了关于“一项多中心、双盲、随机、剂量范围试验，评估康柏西普眼注注射液治疗新生血管性年龄相关性黄斑变性患者的疗效和安全性”全球Ⅲ期临床试验项目(即KH916项目)，而且信心满满地跟阿柏西普(再生元和拜耳联合开发的VEGF单抗)进行头对头比较. 2020年12月，康弘药业还曾计划定增募资34.72亿元，并将其中25.73亿元用于康柏西普的“出海”. 然而，这个历时近3年的创新药“出海”项目最终宣告夭折，近14亿元的研发投入因此打了水漂. " From Google Translate: "In May 2018, Kanghong Pharmaceutical launched "a multi-center, double-blind, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept Ophthalmic Injection in the treatment of patients with neovascular age-related macular degeneration" "Global Phase III clinical trial project (i.e. KH916 project), and confidently conduct a head-to-head comparison with aflibercept (a VEGF monoclonal antibody jointly developed by Regeneron and Bayer). In December 2020, Kanghong Pharmaceutical also planned to raise 3.472 billion yuan in additional capital, of which 2.573 billion yuan would be used for Conbercept's "overseas expansion.""   The article notes: "长江商报记者注意到，康弘药业净利润的增长主要原因之一为，眼科创新药康柏西普全球多中心临床试验停止. 由此导致研发费用等费用下滑，为利润增长打开空间. " From Google Translate: "A reporter from the Changjiang Business Daily noticed that one of the main reasons for the growth of Kanghong Pharmaceutical's net profit was the suspension of global multi-center clinical trials of the innovative ophthalmic drug Conbercept. This has led to a decline in R&D expenses and other expenses, opening up room for profit growth." </li> </ol>There is sufficient coverage in reliable sources to allow Chengdu Kanghong Pharmaceutical Group to pass Notability, which requires "significant coverage in reliable sources that are independent of the subject". Cunard (talk) 01:19, 14 April 2024 (UTC) </li></ul>
 * Keep Cunard's sources are sufficient to meet WP:NCORP, specifically 2/3/4 through a quick skim have the intellectual independence & substantial coverage needed to meet the higher bar. Jumpytoo Talk 19:01, 14 April 2024 (UTC)


 * The above discussion is preserved as an archive of the debate. <b style="color:red">Please do not modify it.</b> Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.